Smileyscope pioneered and patented a powerful new approach to digital therapeutics – virtual reality neuromodulation. 

Smileyscope's innovative therapeutic platform underwent rigorous clinical studies, and has changed pediatric needle practice worldwide. International vascular access guidelines now recommend Smileyscope.

ATENTIV was the first company to pioneer digital therapies for behavioral disorders due to developmental delays of cognitive skills, initially for ADHD. It is combining scientific and clinical rigor, with the ingenuity of the tech industry and the power of big data analytics into a platform of products for use by providers, health care insurers and employers. Atentiv’s products deliver treatments not through a pill but through a creative and immersive action adventure video game to treat cognitive deficiencies and improve symptoms associated with behavioral disorders.

ATENTIV was the first company to pioneer digital therapies for behavioral disorders due to developmental delays of cognitive skills, initially for ADHD. It is combining scientific and clinical rigor, with the ingenuity of the tech industry and the power of big data analytics into a platform of products for use by providers, health care insurers and employers. Atentiv’s products deliver treatments not through a pill but through a creative and immersive action adventure video game to treat cognitive deficiencies and improve symptoms associated with behavioral disorders.

Smileyscope pioneered and patented a powerful new approach to digital therapeutics – virtual reality neuromodulation. Smileyscope's innovative therapeutic platform underwent rigorous clinical studies, and has changed pediatric needle practice worldwide. International vascular access guidelines now recommend Smileyscope. Virtual reality neuromodulation is improving patient and healthcare outcomes. Read on to see how we enhance needle experiences.